99m Tc‑labeled single-domain antibody for SPECT/CT assessment of HER2 expression in diverse cancer types.
Betül AltunayAndreas GoedickeOliver H WinzFabian HertelDirk von MallekLevente K MeszarosGitasha ChandHans-Jürgen BiersackElmar StickelerKatja KraussFelix Manuel MottaghyPublished in: European journal of nuclear medicine and molecular imaging (2022)
RAD201 appears safe for use in humans and is a promising noninvasive tool for discriminating HER2 status in metastatic (breast) cancer, regardless of ongoing HER2-targeted antibody treatment.
Keyphrases
- metastatic breast cancer
- poor prognosis
- papillary thyroid
- computed tomography
- dna damage
- image quality
- squamous cell
- cancer therapy
- contrast enhanced
- magnetic resonance imaging
- pet ct
- pet imaging
- squamous cell carcinoma
- positron emission tomography
- binding protein
- magnetic resonance
- lymph node metastasis
- drug delivery
- childhood cancer